Trends in glioblastoma treatment research: an analysis of clinical trials and literature

被引:12
|
作者
Laba, Aleksander E. [1 ,2 ]
Ziolkowski, Piotr [1 ]
机构
[1] Wroclaw Med Univ, Dept Pathol, K Marcinkowskiego 1 Str, PL-50368 Wroclaw, Poland
[2] Reg Specialist Hosp, Dept Neurol, Wroclaw, Poland
关键词
glioblastoma; treatment; research; clinical trial; literature; review; CENTRAL-NERVOUS-SYSTEM; PRIMARY BRAIN; EPIDEMIOLOGY; TUMORS; TEMOZOLOMIDE; SURVIVAL; SCIENCE; SEARCH;
D O I
10.5603/PJNNS.a2021.0024
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials and peer-reviewed journal publications. Materials and methods. Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov was analysed. Information on interventions' mechanisms of action was obtained from Adisinsig ht. A PubMed search for 'glioblastoma' was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and analyzing data was developed by the authors. Results. 1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified.The distribution of g lioblastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having increased especially since 2006. Publications on identified treatment options comprised 322%. Publications on glioblastoma are cited on average 4.27 times per year. The average specificity of treatment options' publications for glioblastoma is 6.9%. Conclusions. Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their scientific research output. To the best of our knowledge, no such registries have been elaborated before.
引用
收藏
页码:269 / 280
页数:12
相关论文
共 50 条
  • [1] Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: Can survival rates of randomized controlled trials be achieved?
    Paus, Samuel
    Hoffmann, Johannes
    Roeper, Julia
    Griesinger, Frank
    NEURO-ONCOLOGY ADVANCES, 2025, 7 (01)
  • [2] Trends in Immunotherapy Clinical Trials to Treat Glioblastoma: A Look at Progress and Challenges
    Price, Gabrielle
    Rossitto, Christina P.
    Price, Hannah
    Hadjipanayis, Constantinos
    Martini, Michael
    WORLD NEUROSURGERY, 2023, 178 : E819 - E827
  • [3] Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023)
    Yu, Shishi
    Wu, Jinya
    Jing, Yuan
    Lin, Ping
    Lang, Lang
    Xiong, Yifan
    Chen, Wangzhong
    Liu, Wenhua
    Sun, Changpeng
    Lu, Yuntao
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [4] Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis
    Marenco-Hillembrand, Lina
    Wijesekera, Olindi
    Suarez-Meade, Paola
    Mampre, David
    Jackson, Christina
    Peterson, Jennifer
    Trifiletti, Daniel
    Hammack, Julie
    Ortiz, Kyle
    Lesser, Elizabeth
    Spiegel, Matthew
    Prevatt, Calder
    Hawayek, Maria
    Quinones-Hinojosa, Alfredo
    Chaichana, Kaisorn L.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (02) : 297 - 307
  • [5] The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma
    Epistolio, Samantha
    Spina, Paolo
    Zaed, Ismail
    Cardia, Andrea
    Marchi, Francesco
    Frattini, Milo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
  • [6] Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
    Fu, Peng
    He, Yun-Song
    Huang, Qin
    Ding, Tao
    Cen, Yong-Cun
    Zhao, Hong-Yang
    Wei, Xiang
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (05) : 833 - 838
  • [7] Clinicopathological characteristics and treatment of rhabdoid glioblastoma Clinical article
    Babu, Ranjith
    Hatef, Jeffrey
    McLendon, Roger E.
    Cummings, Thomas J.
    Sampson, John H.
    Friedman, Allan H.
    Adamson, Cory
    JOURNAL OF NEUROSURGERY, 2013, 119 (02) : 412 - 419
  • [8] PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
    Hao, Chengcheng
    Chen, Gang
    Zhao, Huishan
    Li, Yan
    Chen, Jianxin
    Zhang, Hongmei
    Li, Shan
    Zhao, Yuze
    Chen, Feng
    Li, Wenbin
    Jiang, Wen G.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
    Ellingson, Benjamin M.
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    NEUROTHERAPEUTICS, 2017, 14 (02) : 307 - 320
  • [10] Systematic Evaluation of Promising Clinical Trials-Gene Silencing for the Treatment of Glioblastoma
    Karaarslan, Numan
    Yilmaz, Ibrahim
    Ozbek, Hanefi
    Caliskan, Tezcan
    Topuk, Savas
    Yasar Sirin, Duygu
    Ates, Ozkan
    TURKISH NEUROSURGERY, 2019, 29 (03) : 328 - 334